Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Фаза 4 Завершено NCT05631795

Кратко

The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer (aBC) with a PIK3CA mutation, whose disease had progressed on or after endocrine-based treatment.

Percentage of Participants With at Least One On-treatment Adverse Events (AEs)

From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months · Percentage of participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Все исследования